BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35948813)

  • 1. Pharmacological attenuation of melanoma by tryptanthrin pertains to the suppression of MITF-M through MEK/ERK signaling axis.
    Shabna A; Antony J; Vijayakurup V; Saikia M; Liju VB; Retnakumari AP; Amrutha NA; Alex VV; Swetha M; Aiswarya SU; Jannet S; Unni US; Sundaram S; Sherin DR; Anto NP; Bava SV; Chittalakkottu S; Ran S; Anto RJ
    Cell Mol Life Sci; 2022 Aug; 79(9):478. PubMed ID: 35948813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous suppression of MITF and BRAF V600E enhanced inhibition of melanoma cell proliferation.
    Kido K; Sumimoto H; Asada S; Okada SM; Yaguchi T; Kawamura N; Miyagishi M; Saida T; Kawakami Y
    Cancer Sci; 2009 Oct; 100(10):1863-9. PubMed ID: 19659611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming MITF-conferred drug resistance through dual AURKA/MAPK targeting in human melanoma cells.
    Pathria G; Garg B; Borgdorff V; Garg K; Wagner C; Superti-Furga G; Wagner SN
    Cell Death Dis; 2016 Mar; 7(3):e2135. PubMed ID: 26962685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populations.
    Hartman ML; Talar B; Sztiller-Sikorska M; Nejc D; Czyz M
    Oncotarget; 2016 Feb; 7(8):9026-40. PubMed ID: 26824319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF.
    Wellbrock C; Rana S; Paterson H; Pickersgill H; Brummelkamp T; Marais R
    PLoS One; 2008 Jul; 3(7):e2734. PubMed ID: 18628967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.
    Müller J; Krijgsman O; Tsoi J; Robert L; Hugo W; Song C; Kong X; Possik PA; Cornelissen-Steijger PD; Geukes Foppen MH; Kemper K; Goding CR; McDermott U; Blank C; Haanen J; Graeber TG; Ribas A; Lo RS; Peeper DS
    Nat Commun; 2014 Dec; 5():5712. PubMed ID: 25502142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TYRP1 mRNA level is stable and MITF-M-independent in drug-naïve, vemurafenib- and trametinib-resistant BRAF
    Hartman ML; Czyz M
    Arch Dermatol Res; 2020 Jul; 312(5):385-392. PubMed ID: 31624899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deciphering the Role of Oncogenic MITFE318K in Senescence Delay and Melanoma Progression.
    Bonet C; Luciani F; Ottavi JF; Leclerc J; Jouenne FM; Boncompagni M; Bille K; Hofman V; Bossis G; Marco de Donatis G; Strub T; Cheli Y; Ohanna M; Luciano F; Marchetti S; Rocchi S; Birling MC; Avril MF; Poulalhon N; Luc T; Hofman P; Lacour JP; Davidson I; Bressac-de Paillerets B; Ballotti R; Marine JC; Bertolotto C
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MEK inhibition remodels the active chromatin landscape and induces SOX10 genomic recruitment in BRAF(V600E) mutant melanoma cells.
    Fufa TD; Baxter LL; Wedel JC; Gildea DE; ; Loftus SK; Pavan WJ
    Epigenetics Chromatin; 2019 Aug; 12(1):50. PubMed ID: 31399133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF
    Smith MP; Rana S; Ferguson J; Rowling EJ; Flaherty KT; Wargo JA; Marais R; Wellbrock C
    Pigment Cell Melanoma Res; 2019 Mar; 32(2):280-291. PubMed ID: 30277012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF/MAPK and GSK3 signaling converges to control MITF nuclear export.
    Ngeow KC; Friedrichsen HJ; Li L; Zeng Z; Andrews S; Volpon L; Brunsdon H; Berridge G; Picaud S; Fischer R; Lisle R; Knapp S; Filippakopoulos P; Knowles H; Steingrímsson E; Borden KLB; Patton EE; Goding CR
    Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8668-E8677. PubMed ID: 30150413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
    Konieczkowski DJ; Johannessen CM; Abudayyeh O; Kim JW; Cooper ZA; Piris A; Frederick DT; Barzily-Rokni M; Straussman R; Haq R; Fisher DE; Mesirov JP; Hahn WC; Flaherty KT; Wargo JA; Tamayo P; Garraway LA
    Cancer Discov; 2014 Jul; 4(7):816-27. PubMed ID: 24771846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma.
    Fernández-Barral A; Orgaz JL; Baquero P; Ali Z; Moreno A; Tiana M; Gómez V; Riveiro-Falkenbach E; Cañadas C; Zazo S; Bertolotto C; Davidson I; Rodríguez-Peralto JL; Palmero I; Rojo F; Jensen LD; del Peso L; Jiménez B
    Neoplasia; 2014 Jun; 16(6):529-42. PubMed ID: 25030625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MITF activity is regulated by a direct interaction with RAF proteins in melanoma cells.
    Estrada C; Mirabal-Ortega L; Méry L; Dingli F; Besse L; Messaoudi C; Loew D; Pouponnot C; Bertolotto C; Eychène A; Druillennec S
    Commun Biol; 2022 Jan; 5(1):101. PubMed ID: 35091687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERK-regulated differential expression of the Mitf 6a/b splicing isoforms in melanoma.
    Primot A; Mogha A; Corre S; Roberts K; Debbache J; Adamski H; Dreno B; Khammari A; Lesimple T; Mereau A; Goding CR; Galibert MD
    Pigment Cell Melanoma Res; 2010 Feb; 23(1):93-102. PubMed ID: 19895547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma.
    Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD
    J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative antiproliferative signaling by aspirin and indole-3-carbinol targets microphthalmia-associated transcription factor gene expression and promoter activity in human melanoma cells.
    Poindexter KM; Matthew S; Aronchik I; Firestone GL
    Cell Biol Toxicol; 2016 Apr; 32(2):103-19. PubMed ID: 27055402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MITF Modulates Therapeutic Resistance through EGFR Signaling.
    Ji Z; Erin Chen Y; Kumar R; Taylor M; Jenny Njauw CN; Miao B; Frederick DT; Wargo JA; Flaherty KT; Jönsson G; Tsao H
    J Invest Dermatol; 2015 Jul; 135(7):1863-1872. PubMed ID: 25789707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.